Neuroprotective effects of acetyl-l-carnitine (ALC) in a chronic MPTP-induced Parkinson’s disease mouse model: Endothelial and microglial effects

• Published in: Neuroscience letters 2019-06, Vol.703, p.86-95
• Main Authors: Burks, Susan, Raymick, James, Robinson, Bonnie, Hanig, Joseph, Sarkar, Sumit
• Format: Article
• Language: English
• Subjects: Acetyl-l-carnitine; Endothelial dysfunction; Microglial activation; Neuroprotection; Parkinson’s disease
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/j.neulet.2019.03.015

•First instance of ALC preventing glial activation in MPTP animals.•First instance of ALC preventing Glut-1, OCL, and ZO-1 loss in MPTP animals.•ALC preventing loss of TH, DAT, and DA confirms 6-OHDA and MPTP model findings.•ALC preventing astrocytic response confirms 6-OHDA model findings. Parkinson’s disease (PD) is a progressive motor disease with clinical features emerging due to degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc), which project to the caudate putamen (CPu) where they release dopamine (DA). The current study investigated whether acetyl-l-carnitine (ALC) could ameliorate the pathology seen in an in vivoin vivo chronic 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced mouse model of PD. Four treatment groups were included: 1) CONTROL receiving probenecid (PROB; 250 mg/kg) only, 2) MPTP (25 mg/kg) + PROB, 3) MPTP + ALC (100 mg/kg), and 4) ALC alone. MPTP-induced losses in tyrosine hydroxylase and DA transporter immunoreactivity in the SNc and CPu were significantly reduced by ALC. HPLC data further suggests that decreases in CPu DA levels produced by MPTP were also attenuated by ALC. Additionally, microglial activation and astrocytic reactivity induced by MPTP were greatly reduced by ALC, indicating protection against neuroinflammation. Glucose transporter-1 and the tight junction proteins occludin and zonula occludins-1 were also protected from MPTP-induced down-regulation by ALC. Together, data suggest that in this model, ALC protects against MPTP-induced damage to endothelial cells and loss of DA neurons in the SNc and CPu, suggesting that ALC therapy may have the potential to slow or ameliorate the progression of PD pathology in a clinical setting.